Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025
Perspective Therapeutics (NYSE AMERICAN: CATX) announced that updated interim results from their Phase 1/2a trial of [212Pb]VMT-α-NET will be presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025, in San Francisco. The presentation, titled 'Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs),' will be featured in Poster Session B.
The company will host a webcast conference call on January 24, 2025, at 8:00 am ET to discuss the presented data. Dr. Richard L. Wahl, lead investigator and Professor of Radiology at Washington University School of Medicine, will participate alongside the management team. The initial results were previously presented with data cut-off on October 31, 2024.
Perspective Therapeutics (NYSE AMERICAN: CATX) ha annunciato che i risultati intermedi aggiornati del loro studio di Fase 1/2a su [212Pb]VMT-α-NET saranno presentati al Simposio ASCO sui Tumori Gastrointestinali il 24 gennaio 2025, a San Francisco. La presentazione, intitolata 'Dati intermedi di sicurezza ed efficacia di [212Pb]VMT-α-NET nei Tumori Neuroendocrini (NETs) che esprimono il Recettore della Somatostatina 2 (SSTR2),' sarà inclusa nella Sessione Poster B.
L'azienda ospiterà una conferenza in webcast il 24 gennaio 2025, alle 8:00 ET, per discutere i dati presentati. Il Dr. Richard L. Wahl, ricercatore principale e Professore di Radiologia presso la Washington University School of Medicine, parteciperà insieme al team dirigenziale. I risultati iniziali erano stati precedentemente presentati con un cutoff dei dati al 31 ottobre 2024.
Perspective Therapeutics (NYSE AMERICAN: CATX) anunció que los resultados intermedios actualizados de su ensayo de Fase 1/2a sobre [212Pb]VMT-α-NET se presentarán en el Simposio ASCO sobre Cánceres Gastrointestinales el 24 de enero de 2025, en San Francisco. La presentación, titulada 'Datos intermedios de seguridad y eficacia de [212Pb]VMT-α-NET en Tumores Neuroendocrinos (NETs) que expresan el Receptor de Somatostatina 2 (SSTR2),' se incluirá en la Sesión de Póster B.
La compañía organizará una conferencia por webcast el 24 de enero de 2025, a las 8:00 am ET para discutir los datos presentados. El Dr. Richard L. Wahl, investigador principal y profesor de Radiología en la Escuela de Medicina de la Universidad de Washington, participará junto al equipo directivo. Los resultados iniciales se presentaron anteriormente con un corte de datos el 31 de octubre de 2024.
Perspective Therapeutics (NYSE AMERICAN: CATX)는 그들의 1/2a Phase 시험에서 [212Pb]VMT-α-NET의 업데이트된 중간 결과가 2025년 1월 24일 샌프란시스코에서 개최되는 ASCO 위장암 심포지엄에서 발표될 것이라고 발표했습니다. 'Somatostatin Receptor 2 (SSTR2)를 발현하는 신경내분비 종양 (NETs)에서 [212Pb]VMT-α-NET의 안전성 및 효능에 대한 중간 데이터'라는 제목의 발표가 포스터 세션 B에서 진행됩니다.
회사는 2025년 1월 24일 오전 8:00 ET에 발표된 데이터를 논의하기 위해 웹캐스트 전화 회의를 개최할 것입니다. 워싱턴 대학교 의과대학 방사선학 교수인 Richard L. Wahl 박사가 경영진 팀과 함께 참여할 것입니다. 초기 결과는 2024년 10월 31일 기준으로 데이터 컷오프와 함께 이전에 발표되었습니다.
Perspective Therapeutics (NYSE AMERICAN: CATX) a annoncé que des résultats intermédiaires mis à jour de leur essai de Phase 1/2a sur [212Pb]VMT-α-NET seront présentés lors du Symposium ASCO sur les Cancers Gastrointestinales le 24 janvier 2025, à San Francisco. La présentation, intitulée 'Données intermédiaires de sécurité et d'efficacité de [212Pb]VMT-α-NET dans les tumeurs neuroendocrines (NETs) exprimant le récepteur de la somatostatine 2 (SSTR2),' sera présentée lors de la Session d'Affiches B.
L'entreprise organisera une conférence téléphonique en webinaire le 24 janvier 2025, à 8h00 ET, pour discuter des données présentées. Le Dr. Richard L. Wahl, chercheur principal et professeur de radiologie à la Washington University School of Medicine, participera aux côtés de l'équipe de direction. Les résultats initiaux avaient été précédemment présentés avec une date de coupure des données au 31 octobre 2024.
Perspective Therapeutics (NYSE AMERICAN: CATX) gab bekannt, dass aktualisierte Zwischenresultate aus ihrer Phase 1/2a Studie zu [212Pb]VMT-α-NET am ASCO-Symposium für Gastrointestinale Krebserkrankungen am 24. Januar 2025 in San Francisco vorgestellt werden. Die Präsentation mit dem Titel 'Zwischenbericht über Sicherheit und Wirksamkeit von [212Pb]VMT-α-NET bei neuroendokrinen Tumoren (NETs), die den Somatostatin-Rezeptor 2 (SSTR2) exprimieren,' wird in der Poster-Session B gezeigt.
Das Unternehmen wird am 24. Januar 2025 um 8:00 Uhr ET eine Webcast-Konferenzschaltung abhalten, um die präsentierten Daten zu erörtern. Dr. Richard L. Wahl, leitender Forscher und Professor für Radiologie an der Washington University School of Medicine, wird zusammen mit dem Managementteam teilnehmen. Die ersten Ergebnisse wurden zuvor mit einem Datenstichdatum vom 31. Oktober 2024 präsentiert.
- None.
- None.
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that an abstract on updated interim results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET (NCT05636618) has been accepted as a poster presentation at the ASCO Gastrointestinal Cancers Symposium (ASCO-GI) taking place on January 23-25, 2025 in San Francisco, CA.
The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)” will be presented as a part of the session “Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract” taking place on Friday, January 24, 2025 (Poster Bd #: F11) at the ASCO-GI symposium.
Perspective will webcast a conference call on Friday, January 24, 2025 at 8:00 am ET to discuss data to be presented at the ASCO-GI symposium. Webcast details will be available on the Events page of the Company's website in advance of the call. The lead investigator of the study, Richard L. Wahl, MD (Professor of Radiology, Mallinckrodt Institute of Radiology at Washington University School of Medicine) will participate, along with members of Perspective’s management team. A live question and answer session will follow the formal presentation.
Initial results from this study were previously presented with a data cut-off date of October 31, 2024.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moeities. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moeities which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatment applications for cancers throughout the body; the Company's ability to make progress in developing treatments for neuroendocrine tumors; the Company's ability to provide targeted and effective treatment options for cancer patients; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moeities; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moeities provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to develop a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations; the Company's clinical development plans and the expected timing thereof; the Company's expectations, beliefs, intentions, and strategies regarding the future; the Company's intentions to improve important aspects of care in cancer treatment; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
FAQ
When will Perspective Therapeutics (CATX) present their [212Pb]VMT-α-NET trial results at ASCO-GI 2025?
What is the focus of CATX's presentation at ASCO-GI 2025?
When is Perspective Therapeutics (CATX) hosting their conference call to discuss ASCO-GI data?
Who will participate in CATX's conference call about the [212Pb]VMT-α-NET trial results?
